Skip to main content

Advertisement

Table 4 Country and Regional comparison of oncogenic HPV in histologically-confirmed CIN 2, CIN 3 or CIS lesions

From: Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand

HPV type New Zealand * (N=356) Australia(N=533) Global regions
Sample weighted mean (%)
n % (95% CI) n % (95% CI) Asia Europe North America South/Central America
16 181 50.8 (45.5-56.2) 274 51.4 (47.1-5.7) 33.7 51.5 33.5 37.6
52β 67 18.8 (14.9-23.3) 74§ 13.9 (11.1-7.1) 9.5 2.0 4.8 4.7
31 62 17.1 (13.4-21.5) 77 14.4 (11.617.7) 5.4 9.5 13.1 6.0
33 47 13.2 (9.9-17.2) 49 9.2 (6.9-12.0) 5.9 8.1 5.0 5.1
18 43 12.1 (8.9-15.9) 49 9.2 (6.9-12.0) 6.6 6.0 8.3 5.4
58β 40 11.5 (8.4-15.3) 37 6.9 (4.9-9.4) 12.2 3.5 6.8 11.2
51 36 10.1 (7.2-13.7) 61 11.4 (8.9-14.5) 5.1 2.0 3.4 4.0
39 27 7.3 (4.8-10.5) 44 8.3 (6.4-11.3) 1.2 1.4 3.7 2.4
35 18 4.8 (2.8-7.5) 24 4.5 (2.9-6.6) 3.3 2.2 2.8 3.9
45 16 4.5 (2.6-7.2) 23 4.3 (3.1-6.8) 0 1.5 2.3 6.0
59 15 4.2 (2.4-6.9) 26 4.9 (3.2-7.1) 2.3 0 1.9 1.0
56 10 2.8 (1.4-5.1) 28 5.3 (3.5-7.5) 3.6 2.9 8.7 2.1
68β 8 2.2 (1.0-4.4) 12 2.3 (1.2-3.9) 1.1 0.2 2.4 0.5
Any β 342 94.9 (92.1-97) 485 91.0 (88.2-3.3) 78.0 87.3 78.8 77.9
  1. Oncogenic HPV includes infection with either type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, or 68; CIN cervical intra-epithelial neoplasia; CIS carcinoma in situ.
  2. * Limited to women with histologically-confirmed CIN 2/3. Excludes AIS, glandular dysplasia or cervical cancer. As discussed in the text, the population was ‘enriched’ because all were originally referred with high grade cytology.
  3. † From Stevens et al. (2009).[9].This study included histologically-confirmed CIN 2+, but squamous cell carcinoma constituted only 9 of 533 cases.
  4. ‡ Re-calculated from data in[24](see text). African region had no studies with HPV type-specific measurement in histologically-confirmed high grade disease.
  5. β Statistically significant difference in prevalence between New Zealand and Australia when compared using HPV prevalence in CIN 2 from both studies.
  6. § HPV type 52 detected via Linear Array in the absence of types 33, 35 or 58; or confirmed via an in-house probe designed to detect type 52 within this subgroup of co-infections. Results for type 52 alone not validated for linear array testing.